In another study, 12 (30.3%) patients treated with BCMA‐targeted CAR‐T cell monotherapy and 16 (45.7%) patients treated with BCMA and CD19 CAR‐T cell co‐therapy developed infections during a mean follow‐up time of 20.5 months. This evidence concerns the gene CD19 and infection.